{"id":390694,"date":"2018-04-30T00:00:00","date_gmt":"2018-04-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0036-2018-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-03-31T10:48:37","modified_gmt":"2026-03-31T10:48:37","slug":"algoim0036-2018-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0036-2018-biopharma-crohns-disease-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Crohn&#8217;s Disease | Treatment Algorithms: Claims Data Analysis | US | 2018"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><\/p>\n<p>U.S. gastroenterologists generally follow a step-up approach when treating Crohn\u2019s disease patients that begins with safe, albeit often less efficacious, therapies (e.g., aminosalicylates) first line, before progressing to more-potent drugs, such as immunosuppressants and\/or biologics. Among the biologics, the\u00a0<abbr data-original-title=\"tumor necrosis factor\" title=\"\">TNF<\/abbr>-alpha inhibitors (e.g., Janssen\/Merck\u2019s Remicade, AbbVie\/Eisai\u2019s Humira) have\u2014and continue to be\u2014the most widely used agents. However, over the past several years, the Crohn\u2019s disease treatment landscape has witnessed the approval of two novel biologics (i.e., Takeda\u2019s Entyvio and Janssen\u2019s Stelara), leading to increasing competition among the biologics, and further expanding physicians\u2019 treatment armamentarium.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed Crohn\u2019s disease patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed Crohn\u2019s disease patients?<\/li>\n<li>How have Entyvio\u00a0and Stelara been integrated into the treatment algorithm?<\/li>\n<li>What percentage of Crohn\u2019s disease patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of Crohn\u2019s disease patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated Crohn\u2019s disease patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis\u00a0provides detailed analysis of brand usage across different lines of therapy using real-world,\u00a0patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing\u00a0brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390694","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390694\/revisions"}],"predecessor-version":[{"id":393818,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390694\/revisions\/393818"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}